Evidence map›Paper›PMID 42227075›Full record

ArticleSmall methods2026

Label-Free Profiling of Immunoglobulin Isotypes Using Solid-State Nanopores.

Iris Baffour Ansah, Kevin J Freedman

Abstract read
In one paragraph

Article in Small methods, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Iris Baffour AnsahDepartment of Bioengineering, University of California, Riverside, California, USA.
Kevin J FreedmanDepartment of Bioengineering, University of California, Riverside, California, USA.

Funding

NanoSMS: single molecule secretome analysis for non-destructive cellular fingerprintingR35GM151115 · NIGMS · UNIVERSITY OF CALIFORNIA RIVERSIDE · PI Kevin Freedman · 2023 to 2026
$1.4M
NIGMS NIH HHS R35 GM151115NIGMS NIH HHS R35GM151115
6 · The paper itself

Abstract

Accurate profiling of antibody isotypes is essential to monitor immune responses, diagnose disease, and guide therapy, yet existing immunoassays remain limited in capturing their conformational dynamics with molecular precision. Nanopore sensing offers a label-free route to such resolution, but most implementations rely on fragmentation, probes, or functionalization, leaving intact isotypes inaccessible. Here, a nanopore-based assay that directly discriminates full-length IgG, monomeric IgA, and IgM under non-denaturing conditions, resolving intrinsic molecular signatures in real time is presented. In a lithium chloride electrolyte, glass nanopipettes operate in an electroosmotic-flow-dominated regime where flow-driven transport and nanoscale confinement produce distinct ionic fingerprints for each isotype. Affinity-based signal modulation with protein G, which selectively binds the IgG Fc domain, further introduces a tunable contrast mechanism that sharpens IgG-IgA separability while preserving native structure and binding functionality. Quantitative analysis demonstrates robust separation (p < 0.0001) in binary and ternary mixtures with low misclassification. Evaluation in diluted human serum with a physiologically representative IgG:IgA:IgM ratio (7:2:1) shows that isotype-specific fingerprints remain distinguishable in a serum-derived background. The EOF-governed assay establishes a scalable framework for direct, multiplexed immunoprofiling and extends label-free nanopore analysis beyond antibodies toward broader proteomic targets.

Indexed as

human serumIgAIgGIgMintact antibody translocationlabel‐freemultiplexed sensingnanopipetteprotein G

Identifiers

PMID42227075
PMCPMC13476987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.